Influenza A Virus, H5N1 Subtype Clinical Trial
Official title:
Randomized, Double-Blinded, Phase 2 Study to Assess Safety and Immunogenicity of Homologous and Heterologous Prime-Boost Vaccination Strategies With Stockpiled Inactivated Monovalent Influenza A(H5) Vaccines Administered Intramuscularly With Either AS03 or MF59® as Adjuvant
The main purpose of this study is to assess the ability of H5 influenza virus vaccines and
adjuvants present in the National Pre-Pandemic Influenza Vaccine Stockpile (NPIVS) to
generate an immune response to homologous and to antigenically distant heterologous H5
influenza virus strains.
The study is designed to evaluate the safety and immunogenicity of vaccination strategies
with homologous or antigenically distant heterologous H5 influenza virus vaccines
administered with AS03 or MF59 adjuvant.
n/a
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT00489931 -
Phase I Open-Label Study of Recombinant DNA Plasmid Vaccine, VRC-AVIDNA036-00-VP, Encoding for Influenza Virus H5 Hemagglutinin Protein Given Intradermally
|
Phase 1 | |
Completed |
NCT01910519 -
Systems Biology of Influenza A (H5N1) Virus Monovalent Vaccine With and Without Adjuvant System 03 (AS03)
|
Phase 2 | |
Completed |
NCT01086657 -
An Open-Label, Randomized Phase I Study in Healthy Adults of the Safety and Immunogenicity of Prime-Boost Intervals With Monovalent Influenza Subunit Virion (H5N1) Vaccine, A/Indonesia/05/2005 (Sanofi Pasteur, Inc.) Administered Alone or Following Re...
|
Phase 1 | |
Completed |
NCT00408109 -
Safety Study of Avian Flu Vaccine
|
Phase 1 | |
Completed |
NCT02107807 -
Safety and Immunogenicity of Two Doses of aH5N1 Vaccine in Adult and Elderly Subjects With and Without Immunosuppressive Conditions *aH5N1:Monovalent H5N1 Influenza Vaccine
|
Phase 3 |